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BACKGROUND: As age increases, prevalence of type 2 diabetes in the U.S. rises
dramatically as the population approaches and enters Medicare eligibility (CDC).
Although ensuring category access, CMS formulary guidelines for Medicare Part D
(MPD) coverage do not take into account the effects of cost-sharing burden on
patient compliance. Literature demonstrates that patient adherence is reduced
with higher copayment costs and consequently, the beneficial clinical impactsmay
likely be unrealized for many patients. OBJECTIVES: To investigate access to dia-
betic medications for MPD patients compared to commercially covered lives. Ex-
ploring copay differentials amongst these populations, insight is gained on how
MPD differs from commercial access to diabetes medications.METHODS: Analysis
of the Walters Kluwer Pharma Solutions Source Longitudinal Patient Database,
sampling of 26.7 million commercial lives and 5 million Medicare Part D lives in
2009. Low Income Subsidy covered lives were excluded. RESULTS: Average drug
copayment for metformin and sulfonylurea for commercial and MPD patients is
$15 and $19 respectively. Average drug copayment for insulin glargine in commer-
cial is $17 and $27 for MPD patients, for branded pioglitazone $31 and $52, and
exenatide $32 and $68. CONCLUSIONS: Copayment differentials across these pop-
ulations are small for generic therapies and grow larger for branded, novel diabetic
agents. This data would suggest a broader, more inclusive review is needed to
assess how the financial burden felt by MPD diabetes patients affects patient com-
pliance and outcomes. Further investigation is needed to study the potential value
that CMS would benefit from re-evaluating the cost sharing burden for this patient
population.
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BIOMARKERS: A CHANGING PARADIGM FOR DEVELOPMENT
Pardini AT, Saraf S, Sparrowhawk K
PriceSpective Ltd., London, UK
The general perception is that pharma companies generally incorporate biomarker
(BM) development into their processes when a drug response is not optimal follow-
ing the results of phase 3 studies. Usually this is when poorer than expected effi-
cacy results are achieved. In this scenario, the BM development enables targeting
of a niche population that is representative of the responders, thus effectively
increasing the efficacy making the product more attractive to payers and health-
care professionals. This late stage approach to BM development also fits with the
commonly held belief that BMs are linked to reduced market access (MA), lower
market shares and decreased product revenues. In such a situation BMs are often
only developed retrospectively to overcome access issues. Our objective is to dem-
onstrate that investment into BMs in the early phase of drug development (DD) is
more commercially attractive. METHODS: Three scenarios of drug development
were defined: 1) the current/traditional model, 2) where biomarker development
is incorporated from phase I of development and 3) where biomarker develop-
ment involves a concurrent Phase III investigation or Phase IV retrospective
analysis. These scenarios were analyzed to determine the relationship between
risk and reward using assumed cash-flow curves and net-present value analysis
based upon those curves. In each case, the implications of integration of BM
development at various stages and how this affects risk-reward were assessed.
RESULTS AND CONCLUSIONS: The scenario analysis demonstrates that by shift-
ing investment to earlier in the DD process, costs associated with investment-
heavy Phase III will be reduced. Early incorporation of BMs into DDwill improve the
commercial and healthcare benefits and the drug will have the potential to benefit
from shortened approval time, early MA and higher price.
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OBJECTIVES: This poster examines the pharmaceutical price implication for rare
disease products in two countries which recently developed technology assess-
ment and pricing processes with a look toward the potential implications for the
United States. METHODS: Case studies are built out of examining prices for the
Multiple Sclerosis drugs interferon beta-1a and natalizumab in the context of Bra-
zil, while the Gaucher’s disease products imiglucerase andmiglustat are studied in
Canada. In each case, a brief overview of the health systems is given, with specific
attention to the pricing bodies. The prices for drugs which came to market before
and after the advent of a pricing body are compared relative to each other. These
differences are then compared to the price differential in the US and UK to deter-
mine if the HTA bodywas instrumental in this pricing change. RESULTS: In Canada
miglustat is 17.8% of the cost for imiglucerase while in the US it is 38%, with a
similar trend in the price of MS drugs in Brazil. To some degree, the lower price is
expected as the drug classes are different. However, the disparity between a 17.8%
differential and a 38% differential suggests that the Canadian pricing body is used
to apply downward pressure on the price of rare disease drugs.CONCLUSIONS:The
price differential has distinct implications for the USmarket, in which payers may
look towards developing a technology assessment process using cost effectiveness
research to drive down costs due to the current environment. As one of the most
important markets for pharmaceutical profits, this has considerable ramifications
for industry in terms of income and innovation incentive.
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We propose a novel applied decision analytics solution in clinical outcomes anal-
ysis for deriving outcomes to be used as benchmarks in designing appropriate
therapies in personalized medicine and predictive pharmacology. The efficacy of
comparative effectiveness research in clinical medicine and pharmacology is lim-
ited by the lack of a defined solution to derive clinical outcomes across diverse
patient populations and a variety of disparate data sources that collectively define
a clinical profile at particular point in time. An outcome at timeT1 is driven not only
by static factors such as race, ethnicity and occupation, that are generally time-
independent, but also by the condition profile and resultant outcome of the pa-
tient’s condition at T0. Our solution is an ensemble analytical framework that
leverages a temporal rule induction algorithm to create derived outcomes profiles
across the time continuum. It performs analysis on structured and unstructured
data from EMR/EHR, clinical, biological, biomarker, behavioral and demographic
data sources that are integrated into a composite data warehouse via our propriety
semantic resolution and natural language processing algorithms. The outcomes
profiles reflect an index or aggregate score for the amalgamation of all available
data for a particular patient at a particular time. Outcomes profiles from thousands
of samples are catalogued and normalized in a registry and are used to establish a
baselinematrix for application in higher level statistical and predictive analyses for
comparative effectiveness studies in pharmacology. Using this approach, it is pos-
sible to determine based on available data both the appropriate treatment to affect
a desired outcomeand the predicted outcomebased on a given treatment at a given
time.
PHP110
BIOSIMILARS LITERATURE REVIEW: THE CURRENT LANDSCAPE AND
IMPLICATIONS OF RECENT HEALTH CARE LEGISLATION FOR THE UNITED
STATES MARKET
Maiese BA, Lee EH, Toscani MT
Jefferson School of Population Health, Philadelphia, PA, USA
Biosimilars represent an emerging area of interest for the pharmaceutical industry.
Biosimilars are essentially ’generic’ versions of ‘branded’ biologics, but are not
considered identical to the innovator biologic. In 2009, half of the top ten selling
drugs were biologics; this proportion is expected to reach 80% by 2015. Biosimilars
are seen as a cost-saving alternative to payers, and as generic drugs take over the
market, manufacturers are depending on biologics to drive growth. However, they
will need to consider the inherent challenges in this market. This literature review
was undertaken to provide a summary of the current state of affairs with biosimi-
lars, including a review of the recent healthcare legislation and policies in coun-
tries that already have formal guidance regarding biosimilars approval. Significant
resources are required to participate in the biosimilars market, including regula-
tory expertise, manufacturing capabilities, and global market reach. One concern
to potential market players is the uncertainty regarding the approval process for
biosimilars in the United States (U.S.). The Patient Protection and Affordable Care
Act (PPACA 2009) authorized the FDA to develop an abbreviated regulatory path-
way for biosimilar approval but guidance has not yet been issued. It is important for
the U.S. to learn from other countries. This review includes a summary of other
countries’ approaches to biosimilars approval. For example, since 2006, the Euro-
pean Medicines Agency has had extensive requirements for pre-clinical and clini-
cal data to demonstrate quality, safety, and efficacy of the product seeking ap-
proval. Questions remain including: How will the competitive landscape look as
biosimilars enter the market? What will be the comfort level with substitutability
of biosimilars?Will there be patent protection for themanufacturing process? And,
what will the FDA require in terms of clinical trials and other supportive data to
recognize biosimilars? The literature review will address these questions and
more.
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The biologicalmodel of schizophrenia remains the dominantmodel withinmental
health services andhas a powerful and enduring influence on the prevailing format
of mental health care delivery to patients with the diagnosis. There exists almost
universal acceptance of a genetic cause for schizophrenia though in many in-
stances this conflicts both philosophically and clinically with a person-centred
recovery orientated approach. A reviewof the underpinning research that supports
the genetic argument was conducted. Appraisal of family, twin and adoption stud-
ies uncovers serious flaws in the methodologies and statistical analyses used in
studies. These flaws tend to artificially inflate the perceived genetic contribution to
schizophrenia and moreover may also invalidate many of the reported study find-
ings. There exists an absence of a replicable and consistent finding indicating a
clear genetic pathway to schizophrenia. Novel therapeutic approaches aimed at
neurotransmitter receptor site abnormalities should not therefore be discouraged
by any fundamental refocus on gene therapy approaches.
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REVIEW
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Chronic Fatigue Syndrome (CFS) is an enigmatic andmisunderstood clinical entity.
A broad range of etiologicalmechanismshave been suggested including endocrine,
immune, infectious, muscular and neurological abnormalities. However, the cause
remains elusive thus impacting on developing models of evidenced based thera-
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